AbbVie Inc (ABBV)vsHalozyme Therapeutics Inc (HALO)
ABBV
AbbVie Inc
$227.23
-2.69%
HEALTHCARE · Cap: $380.57B
HALO
Halozyme Therapeutics Inc
$71.53
-0.10%
HEALTHCARE · Cap: $8.24B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4064% more annual revenue ($62.82B vs $1.51B). HALO leads profitability with a 23.1% profit margin vs 5.8%. HALO trades at a lower P/E of 24.4x. HALO earns a higher WallStSmart Score of 70/100 (B).
ABBV
Buy63
out of 100
Grade: C+
HALO
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for HALO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Every $100 of equity generates 159 in profit
Strong operational efficiency at 49.0%
Revenue surging 42.2% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 31.2% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Grey zone — moderate risk
Weak financial health signals
Trading at 38.7x book value
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 49.0%. Revenue growth of 42.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : HALO
The primary concerns for HALO are Altman Z-Score, Piotroski F-Score, Price/Book. Debt-to-equity of 9.76 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while HALO is a growth play — different risk/reward profiles.
HALO carries more volatility with a beta of 0.87 — expect wider price swings.
HALO is growing revenue faster at 42.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
HALO scores higher overall (70/100 vs 63/100), backed by strong 23.1% margins and 42.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?